Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 167 entries
Sorted by: Best Match Show Resources per page
New orally administered antihyperglycemic agents for the management of patients with type ii diabetes and the syndrome of insulin resistance.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Edelman SV.
PMID: 15251529
Endocr Pract. 1996 Jul-Aug;2(4):271-5. doi: 10.4158/EP.2.4.271.

OBJECTIVE: To describe several newly developed orally administered antidiabetic drugs, which are effective for type II diabetes.METHODS: Detailed clinical information about three types of antihyperglycemic agents--carbohydrase inhibitors, biguanides, and thiazolidinediones--is presented.RESULTS: Miglitol and acarbose, two a-glucosidase inhibitors, effectively reduce...

Cite
Edelman SV. New orally administered antihyperglycemic agents for the management of patients with type ii diabetes and the syndrome of insulin resistance. Endocr Pract. 1996;2(4):271-5doi: 10.4158/EP.2.4.271.
Edelman, S. V. (1996). New orally administered antihyperglycemic agents for the management of patients with type ii diabetes and the syndrome of insulin resistance. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2(4), 271-5. https://doi.org/10.4158/EP.2.4.271
Edelman, S V. "New orally administered antihyperglycemic agents for the management of patients with type ii diabetes and the syndrome of insulin resistance." Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists vol. 2,4 (1996): 271-5. doi: https://doi.org/10.4158/EP.2.4.271
Edelman SV. New orally administered antihyperglycemic agents for the management of patients with type ii diabetes and the syndrome of insulin resistance. Endocr Pract. 1996 Jul-Aug;2(4):271-5. doi: 10.4158/EP.2.4.271. PMID: 15251529.
Copy Download .nbib Format: NLM
Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results.

Archives of drug information

Güler S, Sharma SK, Almustafa M, Kim CH, Azar S, Danciulescu R, Shestakova M, Khutsoane D, Bech OM.
PMID: 19684847
Arch Drug Inf. 2009 Jun;2(2):23-33. doi: 10.1111/j.1753-5174.2008.00015.x.

AIMS: This paper presents the treatment outcomes for patients intiated on biphasic insulin aspart 30 (BIAsp 30) treatment: BIAsp 30-only, BIAsp 30 + sulphonylureas (SU), BIAsp 30 + biguanides (BI), BIAsp 30 + SU + BI, BIAsp 30 +...

Cite
Güler S, Sharma SK, Almustafa M, et al. Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results. Arch Drug Inf. 2009;2(2):23-33doi: 10.1111/j.1753-5174.2008.00015.x.
Güler, S., Sharma, S. K., Almustafa, M., Kim, C. H., Azar, S., Danciulescu, R., Shestakova, M., Khutsoane, D., & Bech, O. M. (2009). Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results. Archives of drug information, 2(2), 23-33. https://doi.org/10.1111/j.1753-5174.2008.00015.x
Güler, Serdar, et al. "Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results." Archives of drug information vol. 2,2 (2009): 23-33. doi: https://doi.org/10.1111/j.1753-5174.2008.00015.x
Güler S, Sharma SK, Almustafa M, Kim CH, Azar S, Danciulescu R, Shestakova M, Khutsoane D, Bech OM. Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results. Arch Drug Inf. 2009 Jun;2(2):23-33. doi: 10.1111/j.1753-5174.2008.00015.x. PMID: 19684847; PMCID: PMC2721962.
Copy Download .nbib Format: NLM
Does atorvastatin work more effectively than biguanides in reducing cardiovascular risk factors?.

Journal of pharmacy & bioallied sciences

Siddiq A, Khan RA, Baig SG.
PMID: 21687364
J Pharm Bioallied Sci. 2011 Apr;3(2):306-9. doi: 10.4103/0975-7406.80767.

Increased risk of coronary artery disease in diabetic persons is associated with increased level of lipoproteins. Usually, such risks are reverted with glycemic control by antidiabetic medicines in Type I diabetes millitus. However, in Type II diabetes mellitus lipid...

Cite
Siddiq A, Khan RA, Baig SG. Does atorvastatin work more effectively than biguanides in reducing cardiovascular risk factors?. J Pharm Bioallied Sci. 2011;3(2):306-9doi: 10.4103/0975-7406.80767.
Siddiq, A., Khan, R. A., & Baig, S. G. (2011). Does atorvastatin work more effectively than biguanides in reducing cardiovascular risk factors?. Journal of pharmacy & bioallied sciences, 3(2), 306-9. https://doi.org/10.4103/0975-7406.80767
Siddiq, Afshan, et al. "Does atorvastatin work more effectively than biguanides in reducing cardiovascular risk factors?." Journal of pharmacy & bioallied sciences vol. 3,2 (2011): 306-9. doi: https://doi.org/10.4103/0975-7406.80767
Siddiq A, Khan RA, Baig SG. Does atorvastatin work more effectively than biguanides in reducing cardiovascular risk factors?. J Pharm Bioallied Sci. 2011 Apr;3(2):306-9. doi: 10.4103/0975-7406.80767. PMID: 21687364; PMCID: PMC3103930.
Copy Download .nbib Format: NLM
Rationale, design and baseline patient characteristics of the optimal type 2 diabetes management including benchmarking and standard treatment study in Greece.

World journal of diabetes

Kostapanos MS, Tsimihodimos V, Elisaf MS, Tzouvelekis E, Nikas N.
PMID: 24567804
World J Diabetes. 2014 Feb 15;5(1):76-83. doi: 10.4239/wjd.v5.i1.76.

AIM: To describe baseline data of the optimal type 2 diabetes management including benchmarking and standard treatment (OPTIMISE) study in Greece.METHODS: "Benchmarking" is the process of receiving feedback comparing one's performance with that of others. The OPTIMISE (NCT00681850) study...

Cite
Kostapanos MS, Tsimihodimos V, Elisaf MS, et al. Rationale, design and baseline patient characteristics of the optimal type 2 diabetes management including benchmarking and standard treatment study in Greece. World J Diabetes. 2014;5(1):76-83doi: 10.4239/wjd.v5.i1.76.
Kostapanos, M. S., Tsimihodimos, V., Elisaf, M. S., Tzouvelekis, E., & Nikas, N. (2014). Rationale, design and baseline patient characteristics of the optimal type 2 diabetes management including benchmarking and standard treatment study in Greece. World journal of diabetes, 5(1), 76-83. https://doi.org/10.4239/wjd.v5.i1.76
Kostapanos, Michael S, et al. "Rationale, design and baseline patient characteristics of the optimal type 2 diabetes management including benchmarking and standard treatment study in Greece." World journal of diabetes vol. 5,1 (2014): 76-83. doi: https://doi.org/10.4239/wjd.v5.i1.76
Kostapanos MS, Tsimihodimos V, Elisaf MS, Tzouvelekis E, Nikas N. Rationale, design and baseline patient characteristics of the optimal type 2 diabetes management including benchmarking and standard treatment study in Greece. World J Diabetes. 2014 Feb 15;5(1):76-83. doi: 10.4239/wjd.v5.i1.76. PMID: 24567804; PMCID: PMC3932430.
Copy Download .nbib Format: NLM
The prelude on novel receptor and ligand targets involved in the treatment of diabetes mellitus.

Advanced pharmaceutical bulletin

Jonnalagadda VG, Ram Raju AV, Pittala S, Shaik A, Selkar NA.
PMID: 24754003
Adv Pharm Bull. 2014;4(3):209-17. doi: 10.5681/apb.2014.031. Epub 2014 Feb 07.

Metabolic disorders are a group of disorders, due to the disruption of the normal metabolic process at a cellular level. Diabetes Mellitus and Tyrosinaemia are the majorly reported metabolic disorders. Among them, Diabetes Mellitus is a one of the...

Cite
Jonnalagadda VG, Ram Raju AV, Pittala S, et al. The prelude on novel receptor and ligand targets involved in the treatment of diabetes mellitus. Adv Pharm Bull. 2014;4(3):209-17doi: 10.5681/apb.2014.031.
Jonnalagadda, V. G., Ram Raju, A. V., Pittala, S., Shaik, A., & Selkar, N. A. (2014). The prelude on novel receptor and ligand targets involved in the treatment of diabetes mellitus. Advanced pharmaceutical bulletin, 4(3), 209-17. https://doi.org/10.5681/apb.2014.031
Jonnalagadda, Venu Gopal, et al. "The prelude on novel receptor and ligand targets involved in the treatment of diabetes mellitus." Advanced pharmaceutical bulletin vol. 4,3 (2014): 209-17. doi: https://doi.org/10.5681/apb.2014.031
Jonnalagadda VG, Ram Raju AV, Pittala S, Shaik A, Selkar NA. The prelude on novel receptor and ligand targets involved in the treatment of diabetes mellitus. Adv Pharm Bull. 2014;4(3):209-17. doi: 10.5681/apb.2014.031. Epub 2014 Feb 07. PMID: 24754003; PMCID: PMC3992955.
Copy Download .nbib Format: NLM
Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability.

Frontiers in pharmacology

Barbieri F, Würth R, Pattarozzi A, Verduci I, Mazzola C, Cattaneo MG, Tonelli M, Solari A, Bajetto A, Daga A, Vicentini LM, Mazzanti M, Florio T.
PMID: 30186163
Front Pharmacol. 2018 Aug 21;9:899. doi: 10.3389/fphar.2018.00899. eCollection 2018.

The antidiabetic biguanide metformin exerts antiproliferative effects in different solid tumors. However, during preclinical studies, metformin concentrations required to induce cell growth arrest were invariably within the mM range, thus difficult to translate in a clinical setting. Consequently, the...

Cite
Barbieri F, Würth R, Pattarozzi A, et al. Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability. Front Pharmacol. 2018;9:899doi: 10.3389/fphar.2018.00899.
Barbieri, F., Würth, R., Pattarozzi, A., Verduci, I., Mazzola, C., Cattaneo, M. G., Tonelli, M., Solari, A., Bajetto, A., Daga, A., Vicentini, L. M., Mazzanti, M., & Florio, T. (2018). Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability. Frontiers in pharmacology, 9899. https://doi.org/10.3389/fphar.2018.00899
Barbieri, Federica, et al. "Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability." Frontiers in pharmacology vol. 9 (2018): 899. doi: https://doi.org/10.3389/fphar.2018.00899
Barbieri F, Würth R, Pattarozzi A, Verduci I, Mazzola C, Cattaneo MG, Tonelli M, Solari A, Bajetto A, Daga A, Vicentini LM, Mazzanti M, Florio T. Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability. Front Pharmacol. 2018 Aug 21;9:899. doi: 10.3389/fphar.2018.00899. eCollection 2018. PMID: 30186163; PMCID: PMC6110922.
Copy Download .nbib Format: NLM
Metformin: Focus on Melanoma.

Frontiers in endocrinology

Jaune E, Rocchi S.
PMID: 30186236
Front Endocrinol (Lausanne). 2018 Aug 21;9:472. doi: 10.3389/fendo.2018.00472. eCollection 2018.

Metformin is the most common biguanide used in the treatment of diabetes, with 120 million treated patients worldwide. Metformin decreases hyperglycemia without inducing hypoglycemia in diabetic patients and is very well tolerated. The principal effects of metformin are to...

Cite
Jaune E, Rocchi S. Metformin: Focus on Melanoma. Front Endocrinol (Lausanne). 2018;9:472doi: 10.3389/fendo.2018.00472.
Jaune, E., & Rocchi, S. (2018). Metformin: Focus on Melanoma. Frontiers in endocrinology, 9472. https://doi.org/10.3389/fendo.2018.00472
Jaune, Emilie, and Rocchi, Stéphane. "Metformin: Focus on Melanoma." Frontiers in endocrinology vol. 9 (2018): 472. doi: https://doi.org/10.3389/fendo.2018.00472
Jaune E, Rocchi S. Metformin: Focus on Melanoma. Front Endocrinol (Lausanne). 2018 Aug 21;9:472. doi: 10.3389/fendo.2018.00472. eCollection 2018. PMID: 30186236; PMCID: PMC6110909.
Copy Download .nbib Format: NLM
The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells.

Stem cells international

Yakisich JS, Azad N, Kaushik V, Iyer AKV.
PMID: 30918522
Stem Cells Int. 2019 Feb 21;2019:6254269. doi: 10.1155/2019/6254269. eCollection 2019.

The biguanides metformin (MET) and to a lesser extent buformin (BUF) have recently been shown to exert anticancer effects. In particular, MET targets cancer stem cells (CSCs) in a variety of cancer types but these compounds have not been...

Cite
Yakisich JS, Azad N, Kaushik V, et al. The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells. Stem Cells Int. 2019;2019:6254269doi: 10.1155/2019/6254269.
Yakisich, J. S., Azad, N., Kaushik, V., & Iyer, A. K. V. (2019). The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells. Stem cells international, 20196254269. https://doi.org/10.1155/2019/6254269
Yakisich, Juan Sebastian, et al. "The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells." Stem cells international vol. 2019 (2019): 6254269. doi: https://doi.org/10.1155/2019/6254269
Yakisich JS, Azad N, Kaushik V, Iyer AKV. The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells. Stem Cells Int. 2019 Feb 21;2019:6254269. doi: 10.1155/2019/6254269. eCollection 2019. PMID: 30918522; PMCID: PMC6409035.
Copy Download .nbib Format: NLM
Assessment of disinfectant and antibiotic susceptibility patterns and multi-locus variable number tandem repeat analysis of .

Iranian journal of microbiology

Asadollahi P, Jabalameli F, Beigverdi R, Emaneini M.
PMID: 29997748
Iran J Microbiol. 2018 Apr;10(2):90-97.

BACKGROUND AND OBJECTIVES: Variable number tandem repeat (VNTR) patterns and resistance against three commonly used hospital disinfectants [0.5% (w/w) chlorhexidine digluconate (CHG) and 75% (w/w) alcohol (A), CHG-A; Quaternary ammonium compounds (QACs) and biguanides (B), QAC-B; and 70% (w/w)...

Cite
Asadollahi P, Jabalameli F, Beigverdi R, et al. Assessment of disinfectant and antibiotic susceptibility patterns and multi-locus variable number tandem repeat analysis of . Iran J Microbiol. 2018;10(2):90-97
Asadollahi, P., Jabalameli, F., Beigverdi, R., & Emaneini, M. (2018). Assessment of disinfectant and antibiotic susceptibility patterns and multi-locus variable number tandem repeat analysis of . Iranian journal of microbiology, 10(2), 90-97.
Asadollahi, Parisa, et al. "Assessment of disinfectant and antibiotic susceptibility patterns and multi-locus variable number tandem repeat analysis of ." Iranian journal of microbiology vol. 10,2 (2018): 90-97.
Asadollahi P, Jabalameli F, Beigverdi R, Emaneini M. Assessment of disinfectant and antibiotic susceptibility patterns and multi-locus variable number tandem repeat analysis of . Iran J Microbiol. 2018 Apr;10(2):90-97. PMID: 29997748; PMCID: PMC6039456.
Copy Download .nbib Format: NLM
Sulfonamide metformin derivatives induce mitochondrial-associated apoptosis and cell cycle arrest in breast cancer cells.

Chemico-biological interactions

Markowicz-Piasecka M, Huttunen J, Zajda A, Sikora J, Huttunen KM.
PMID: 34953865
Chem Biol Interact. 2022 Jan 25;352:109795. doi: 10.1016/j.cbi.2021.109795. Epub 2021 Dec 23.

Metformin, an oral anti-diabetic drug, has attracted scientific attention due to its anti-cancer effects. This biguanide exerts preventive effects against cancer, and interferes with cancer-promoting signaling pathways at the cellular level. However, the direct cytotoxic or anti-proliferative effect of...

Cite
Markowicz-Piasecka M, Huttunen J, Zajda A, et al. Sulfonamide metformin derivatives induce mitochondrial-associated apoptosis and cell cycle arrest in breast cancer cells. Chem Biol Interact. 2021;352:109795doi: 10.1016/j.cbi.2021.109795.
Markowicz-Piasecka, M., Huttunen, J., Zajda, A., Sikora, J., & Huttunen, K. M. (2022). Sulfonamide metformin derivatives induce mitochondrial-associated apoptosis and cell cycle arrest in breast cancer cells. Chemico-biological interactions, 352109795. https://doi.org/10.1016/j.cbi.2021.109795
Markowicz-Piasecka, Magdalena, et al. "Sulfonamide metformin derivatives induce mitochondrial-associated apoptosis and cell cycle arrest in breast cancer cells." Chemico-biological interactions vol. 352 (2022): 109795. doi: https://doi.org/10.1016/j.cbi.2021.109795
Markowicz-Piasecka M, Huttunen J, Zajda A, Sikora J, Huttunen KM. Sulfonamide metformin derivatives induce mitochondrial-associated apoptosis and cell cycle arrest in breast cancer cells. Chem Biol Interact. 2022 Jan 25;352:109795. doi: 10.1016/j.cbi.2021.109795. Epub 2021 Dec 23. PMID: 34953865.
Copy Download .nbib Format: NLM
Novel Tetrazoles against Acanthamoeba castellanii Belonging to the T4 Genotype.

Chemotherapy

Wehelie YI, Khan NA, Fatima I, Anwar A, Kanwal K, Khan KM, Siddiqui R, Anwar A.
PMID: 34724675
Chemotherapy. 2021 Nov 01; doi: 10.1159/000520585. Epub 2021 Nov 01.

BACKGROUND: Acanthamoeba castellanii is a pathogenic free-living amoeba responsible for blinding keratitis and fatal granulomatous amoebic encephalitis. However, treatments are not standardized but can involve the use of amidines, biguanides, and azoles.OBJECTIVES: The aim of this study was to...

Cite
Wehelie YI, Khan NA, Fatima I, et al. Novel Tetrazoles against Acanthamoeba castellanii Belonging to the T4 Genotype. Chemotherapy. 2021;doi: 10.1159/000520585.
Wehelie, Y. I., Khan, N. A., Fatima, I., Anwar, A., Kanwal, K., Khan, K. M., Siddiqui, R., & Anwar, A. (2021). Novel Tetrazoles against Acanthamoeba castellanii Belonging to the T4 Genotype. Chemotherapy, . https://doi.org/10.1159/000520585
Wehelie, Yassmin Isse, et al. "Novel Tetrazoles against Acanthamoeba castellanii Belonging to the T4 Genotype." Chemotherapy vol. (2021). doi: https://doi.org/10.1159/000520585
Wehelie YI, Khan NA, Fatima I, Anwar A, Kanwal K, Khan KM, Siddiqui R, Anwar A. Novel Tetrazoles against Acanthamoeba castellanii Belonging to the T4 Genotype. Chemotherapy. 2021 Nov 01; doi: 10.1159/000520585. Epub 2021 Nov 01. PMID: 34724675.
Copy Download .nbib Format: NLM
Sulfonamide metformin derivatives induce mitochondrial-associated apoptosis and cell cycle arrest in breast cancer cells.

Chemico-biological interactions

Markowicz-Piasecka M, Huttunen J, Zajda A, Sikora J, Huttunen KM.
PMID: 34953865
Chem Biol Interact. 2021 Dec 23;352:109795. doi: 10.1016/j.cbi.2021.109795. Epub 2021 Dec 23.

Metformin, an oral anti-diabetic drug, has attracted scientific attention due to its anti-cancer effects. This biguanide exerts preventive effects against cancer, and interferes with cancer-promoting signaling pathways at the cellular level. However, the direct cytotoxic or anti-proliferative effect of...

Cite
Markowicz-Piasecka M, Huttunen J, Zajda A, et al. Sulfonamide metformin derivatives induce mitochondrial-associated apoptosis and cell cycle arrest in breast cancer cells. Chem Biol Interact. 2021;352:109795doi: 10.1016/j.cbi.2021.109795.
Markowicz-Piasecka, M., Huttunen, J., Zajda, A., Sikora, J., & Huttunen, K. M. (2021). Sulfonamide metformin derivatives induce mitochondrial-associated apoptosis and cell cycle arrest in breast cancer cells. Chemico-biological interactions, 352109795. https://doi.org/10.1016/j.cbi.2021.109795
Markowicz-Piasecka, Magdalena, et al. "Sulfonamide metformin derivatives induce mitochondrial-associated apoptosis and cell cycle arrest in breast cancer cells." Chemico-biological interactions vol. 352 (2021): 109795. doi: https://doi.org/10.1016/j.cbi.2021.109795
Markowicz-Piasecka M, Huttunen J, Zajda A, Sikora J, Huttunen KM. Sulfonamide metformin derivatives induce mitochondrial-associated apoptosis and cell cycle arrest in breast cancer cells. Chem Biol Interact. 2021 Dec 23;352:109795. doi: 10.1016/j.cbi.2021.109795. Epub 2021 Dec 23. PMID: 34953865.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 167 entries